1-(3-氯苯胺基)-4-苯基酞嗪
1-(3-氯苯胺基)-4-苯基酞嗪 性质
| 沸点 | 539.7±50.0 °C(Predicted) |
|---|---|
| 密度 | 1.310±0.06 g/cm3(Predicted) |
| 储存条件 | Store at RT |
| 溶解度 | DMF：2mg/mL； DMSO：2mg/mL； DMSO:PBS(pH 7.2) (1:2): 0.3 mg/mL |
| 酸度系数(pKa) | 4.91±0.30(Predicted) |
| 形态 | 黄色固体 |
| 颜色 | 白色至浅黄色至浅橙色 |
1-(3-氯苯胺基)-4-苯基酞嗪 用途与合成方法
|
PDE5 1.3 μM (Ki) |
PDE5 6.7 μM (IC 50 ) |
PDE4 37 μM (IC 50 ) |
MY-5445 inhibits human platelet aggregation by increasing cyclic GMP content and that it provides a useful probe for elucidating the role of cyclic GMP in platelet aggregation .
MY-5445 selectively reverses ABCG2-mediated multidrug resistance in ABCG2-overexpressing cells.
MY-5445 reverses ABCG2-mediated multidrug resistance (MDR) by potentiating the cytotoxicity of an ABCG2 substrate drug in ABCG2-overexpressing multidrug-resistant cancer cells, possibly by modulating the function and/or the protein expression of ABCG2.
MY-5445 (3 μM; 48 hours) substantially increases the topotecan-induced apoptosis in S1-M1-80 cell.
Apoptosis Analysis
| Cell Line: | Human S1 colon cancer cells, S1-M1-80 cancer cells |
| Concentration: | 3 μM |
| Incubation Time: | 48 hours |
| Result: | Enhanced drug-induced apoptosis in ABCG2-overexpressing cancer cells. |
MY-5445 (0.5-3 mg/kg; i.p.; twice a day; for 15 days) produces a significant relief of mechanical hypersensitivity.
| Animal Model: | C57BL/6J male mice |
| Dosage: | 0.5 mg/kg, 3 mg/kg |
| Administration: | Intraperitoneal injection, twice a day, for 15 days |
| Result: | Alleviated the cuff-induced allodynia. |
1-(3-氯苯胺基)-4-苯基酞嗪 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2024-11-08 | HY-100933 | 1 mg | 304 | ||
| 2024-11-08 | HY-100933 | 1-(3-氯苯胺基)-4-苯基酞嗪 | 78351-75-4 | 5mg | 900 |
